Lineweaver Wealth Advisors LLC Invests $646,000 in Boston Scientific Corporation $BSX

Lineweaver Wealth Advisors LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, HoldingsChannel reports. The firm purchased 6,618 shares of the medical equipment provider’s stock, valued at approximately $646,000.

A number of other institutional investors have also modified their holdings of BSX. Vanguard Group Inc. lifted its stake in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. State Street Corp increased its stake in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC lifted its position in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. grew its holdings in shares of Boston Scientific by 1.4% in the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after purchasing an additional 226,578 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.5%

Shares of BSX stock opened at $95.61 on Friday. The company has a market capitalization of $141.74 billion, a P/E ratio of 51.13, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average is $98.64 and its two-hundred day moving average is $101.26. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the company earned $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 143,095 shares of company stock worth $14,228,950. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. The Goldman Sachs Group reiterated a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Royal Bank Of Canada boosted their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Truist Financial decreased their price objective on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $124.85.

Key Stores Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.